Viking Therapeutics (VKTX) Proxy filing summary

Executive summary

• Annual stockholder meeting scheduled for May 19, 2026, to be held virtually.

• Proxy materials, including the annual report and proxy statement, are available online for review and voting.

Voting matters and shareholder proposals

• Election of two Class II director nominees, J. Matthew Singleton and S. Kathryn Rouan, Ph.D., for terms expiring in 2029.

• Ratification of CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote to approve compensation of named executive officers.

• Board recommends voting for all nominees and proposals.

Board of directors and corporate governance

• Board has nominated two individuals for Class II director positions with terms expiring in 2029.